|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Neuroscience Drug Discovery (S.T., M.J.P., G.T., C.G., T.N., L.S., R.A.M., N.J.L.) and Lead Discovery and Profiling (R.J.K., D.G.H., D.W.), Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut
BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine] produced a concentration-dependent membrane hyperpolarization of cultured human bladder myocytes, assessed as either a reduction in fluorescence of the voltage-sensitive dye bis-(1,2-dibutylbarbituric acid)trimethine oxonol (EC50 = 1.26 ± 0.6 µM) or by direct electrophysiological measurement (EC50 = 1.49 ± 0.08 µM). BL-1249 also produced a membrane hyperpolarization of acutely dissociated rat bladder myocytes. Voltage-clamp studies in human bladder cells revealed that BL-1249 activated an instantaneous, noninactivating current that reversed near EK. The BL-1249-evoked outward K+ current was insensitive to blockade by glyburide, tetraethylammonium, iberiotoxin, 4-aminopyridine, apamin, or Mg2+. However, the current was inhibited by extracellular Ba2+ (10 mM). In in vitro organ bath experiments, BL-1249 produced a concentration-dependent relaxation of 30 mM KCl-induced contractions in rat bladder strips (EC50 = 1.12 ± 0.37 µM), yet had no effect on aortic strips up to the highest concentration tested (10 µM). The bladder relaxation produced by BL-1249 was partially blocked by Ba2+ (1 and 10 mM) but not by apamin, iberiotoxin, 4-aminopyridine, glyburide, or tetraethylammonium. In an anesthetized rat model, BL-1249 (1 mg/kg i.v.) decreased the number of isovolumic contractions, without significantly affecting blood pressure. Thus, BL-1249 behaves as a potassium channel activator that exhibits bladder versus vascular selectivity both in vitro and in vivo. A survey of potassium channels exhibiting sensitivity to extracellular Ba2+ at millimolar concentration revealed that the expression of the K2P2.1 (TREK-1) channel was relatively high in human bladder cells versus human aortic cells, suggesting this channel as a possible candidate target for BL-1249.
Address correspondence to: Dr. Svetlana Tertyshnikova, Bristol-Myers Squibb Pharmaceutical Research Institute, Neuroscience Drug Discovery, 5 Research Parkway, Wallingford, CT 06492-7660. E-mail: svetlana.tertyshnikova{at}bms.com
This article has been cited by other articles:
![]() |
E. S. R. Lashinger, M. S. Steiginga, J. P. Hieble, L. A. Leon, S. D. Gardner, R. Nagilla, E. A. Davenport, B. E. Hoffman, N. J. Laping, and X. Su AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome Am J Physiol Renal Physiol, September 1, 2008; 295(3): F803 - F810. [Abstract] [Full Text] [PDF] |
||||